Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
What are the Ovaries?
The ovaries are a pair of organs in the female reproductive system that produce eggs and female hormones.
Evolutionary forces drive a glaring gender imbalance in the occurrence of many health conditions, including autism, a team of genetics researchers has concluded.
Unlike many of us during the COVID-19 pandemic, biological cells are not isolated from the outside world. Chemical variations, intercellular activity, and other microenvironmental factors impact cell survival.
Researchers at Mayo Clinic have combined results from a functional test measuring the effect of inherited variants in the BRCA2 breast and ovarian cancer gene with clinical information from women who received genetic testing to determine the clinical importance of many BRCA2 variants of uncertain significance (VUS).
Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment.
Considered the most lethal form of DNA damage, double-strand breaks must be repaired to prevent cell death. In developing therapies for hard-to-treat breast and ovarian cancers in patients with BRCA gene mutations, scientists aim to identify ways to keep cancer cells from using DNA break repair pathways.
A study led by researchers at the University of Minnesota Medical School found a way to detect the presence of ovarian cancer in patients using Pap test samples, normally used to detect cervical cancer.
When her gynecologist recommended genetic testing, Mai Tran was reluctant.
The European Union has funded a project to improve personalized treatments for ovarian cancer with nearly 15 million euros for five years. The international DECIDER project has partners from 14 organizations in seven EU countries.
The 5-year research project involves 14 organizations in seven EU countries and is funded by €15 M from the EU.
A new drug candidate has been discovered by the University of South Australia to treat the most lethal form of brain cancer - glioblastoma - which kills 95 per cent of patients within five years.
Muscle wasting, or the loss of muscle tissue, is a common problem for people with cancer, but the precise mechanisms have long eluded doctors and scientists. Now, a new study led by Penn State researchers gives new clues to how muscle wasting happens on a cellular level.
The prognosis of ovarian cancer is poor, with an estimated five-year survival of only 40% for advanced disease, the stage at which most ovarian carcinomas are diagnosed.
Oncotarget published "The pro-apoptotic actions of 2-methoxyestradiol against ovarian cancer involve catalytic activation of PKCδ signaling" which reported that the authors have previously shown that a flaxseed-supplemented diet decreases both the incidence and severity of ovarian cancer in laying hens, also induces CYP1A1 expression in liver.
Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.
Researchers from the University Hospitals in Zurich and Basel, ETH Zurich, University of Zurich and the pharmaceutical company Roche have set out to improve cancer diagnostics by developing a platform of state-of-the-art molecular biology methods.
These studies were supported financially by the Medtronic Chair in Surgical Training and Research and a research grant from the Carlos III-FEDER Institute of Health.
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according to a study by The Wistar Institute published online in Nature Cancer.
A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumor biopsies, has been developed by cancer researchers at the University of Cambridge.
A comprehensive study from Uppsala University, involving more than 250,000 women, shows that oral contraceptive use protects against ovarian and endometrial cancer. The protective effect remains for several decades after discontinuing the use. The study is published in the journal Cancer Research.
Deep Longevity, a Hong-Kong based longevity startup, has published their research on the epigenetics of aging in the Aging and Disease journal.